On May 31, 2018 Nordic Nanovector ASA (OSE: NANO) reported that it will present a poster describing a preclinical analysis of genetic factors that correlate with the responsiveness of non-Hodgkin’s lymphoma (NHL) cell lines to Betalutin (177Lu-lilotomab satetraxetan) at the 23rd annual meeting of the European Hematology Association (EHA) (Free EHA Whitepaper) (Stockholm, Sweden, 14-17 June) (Press release, Nordic Nanovector, MAY 31, 2018, View Source [SID1234553501]). This preclinical study highlights the generally promising activity of Betalutin against diffuse large B-cell lymphoma (DLBCL) cell lines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract is available online (click here) and the poster will be available on the company’s website at: www.nordicnanovector.com following the presentation on 15 June.

Poster details

Abstract PF642

Abstract title: Systems biology analysis of responsiveness of non-Hodgkin lymphoma B-cell lines to CD37 targeting radioimmunotherapy

Authors: Melhus, KB et al.

Date: Friday 15 June

Time: 17:30-19:00 (CEST)